Akebia Therapeutics, Inc.
AKBA
$1.58
$0.010.64%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 57.01% | 43.13% | 75.84% | -17.26% | -10.98% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 57.01% | 43.13% | 75.84% | -17.26% | -10.98% |
| Cost of Revenue | 73.66% | 29.13% | 200.66% | -9.02% | -39.98% |
| Gross Profit | 53.88% | 46.41% | 64.50% | -18.82% | -2.10% |
| SG&A Expenses | 9.72% | -1.34% | 1.20% | 8.80% | 16.76% |
| Depreciation & Amortization | -- | -- | -- | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.78% | -6.92% | -6.90% | 6.30% | -9.07% |
| Operating Income | 135.58% | 272.51% | 195.72% | -441.88% | 2.81% |
| Income Before Tax | 105.76% | 102.88% | 133.98% | -3,814.01% | -38.30% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 102.69% | 102.88% | 133.98% | -3,814.01% | -38.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 102.69% | 102.88% | 133.98% | -3,814.01% | -38.30% |
| EBIT | 135.58% | 272.51% | 195.72% | -441.88% | 2.81% |
| EBITDA | 252.25% | 1,124.05% | 384.78% | -106.10% | 9.51% |
| EPS Basic | 102.10% | 102.20% | 129.61% | -3,359.38% | -23.93% |
| Normalized Basic EPS | 104.54% | 103.32% | 132.55% | -837.50% | -25.26% |
| EPS Diluted | 102.00% | 102.20% | 128.89% | -3,359.38% | -30.04% |
| Normalized Diluted EPS | 104.37% | 103.32% | 131.58% | -837.50% | -25.26% |
| Average Basic Shares Outstanding | 25.88% | 25.21% | 14.90% | 15.16% | 11.71% |
| Average Diluted Shares Outstanding | 30.44% | 29.28% | 17.88% | 14.80% | 11.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |